Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
This new test could “play an important role” in screening people who are at risk for developing hepatocellular carcinoma.
Researchers have challenged findings from a Chinese study that concluded Baraclude is tied to a lower risk of liver cancer.
Researchers used an insurance database to estimate the hep B diagnosis rate.
A recent Swedish study defined a low-level detectable viral load as between 50 and 999.
This benefit was independent of weight control among the animals.
Some experts have doubted the link between sustained virologic response and clinical outcomes.
A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.
The International Liver Conference will be held in August 2020.
We all know the rules for living post-op, but this new strain has me feeling even more restricted.
A triple regimen of Opdivo, Yervoy and Cabometyx showed good activity, but side effects may limit its use.
Transplants due to hepatitis C have declined dramatically thanks to effective treatment.
Those with fatty liver disease and cirrhosis should undergo regular screening.
TRK inhibitor larotrectinib led to durable responses in people with colon, pancreatic, appendix, bile duct and liver cancers.
Tecentriq plus Avastin improved improved overall survival and patient experiences during treatment.
Americans are drinking more, which puts them at risk of alcohol-related liver disease, heart disease, cancer and accidents.
The LIVER Act would increase funding for liver cancer and hepatitis B research and prevention.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.